難治例に対する新抗てんかん剤P−3981（Crampol）の臨床治験

TREATMENT OF REFRACTORY EPILEPSY WITH P-3981 (Crampol), A NEW ANTI-CONVULSANT

まえがき

　現在，多数の抗てんかん剤についてそれぞれの報告があり，発作の完全抑制はおよそ50％，有効例数はおよそ80％とかなりの効果が認められている^5）。しかし，全てんかん者のうちにはなお難治のものが20〜30％みいだされ，従つて薬剤による発作抑制を求めて努力しなければならぬ現状は見逃すことはできない^6）。

　最近，Ureide系の新しい抗てんかん剤P−3981（Crampol）が開発された（大日本製薬株式会社）。これは種々のけいれん発現剤に対して強く抵抗し，反面，毒性もかなり弱く，かつ軽度のtranqui—lizer的作用を有することも認められた^1）。P−3981は白色・無臭・結晶性粉末で，水に難溶性である。その構造式を第1図に示す。

In 27 refractory epileptic patients, P-3981 (Crampol), a new anti-convulsant, initially synthesized in Japan, has been administered for duration of 30 to 60 days by means of additional treatment to the routine anticon-vulsive drugs. The results were as follows:

1) In a group of 22 cases with 26 seizure of the total number, who had been maintain-ed the previous basic anticonvulsants, 15 seizures (58%) were brought under complete or excellent control by adding P-3981, showing effect on every seizure type. However, there remained 8 seizures of unchanged and 3 ones of aggravated.

2) In 3 out of 5 cases who had been with-drawn the basic anticonvulsants just before adding P-3981, some favourable effects of P-3981 were clinically recognized.

3) Slight side effects were presented in 2 patients.

4) These results might suggest that P-3981 is available for clinical usage in treat-ment of epilepsy, especially by adding admi-nistration upon the basic anticonvulsive me-dication.